Evotec acquires stake in Exscientia
German CRO Evotec AG announced an €15m investment in British Exscienta Ltd. to push artificial intelligence (AI)-driven drug discovery.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Genmab bags €25m milestone upon market approval of daratumumab
Danish Genmab A/S has received market approval in Japan for its anti-CD38 antibody daratumumab (DARZALEX®) as therapy for relapsed or refractory Multiple Myeloma.
Newron raises CHF27m
Neurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process.
EU approves Roche’s atezolizumab for bladder cancer
Though not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roche’s checkpoint blocker Tecentriq in two types of metastatic bladder cancer.
Da Volterra bags €20m EIB investment
French microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections.
microRNA blocks life-threatening ARDS
A team of US and German researchers has found that neutrophils secrete a regulatory RNA into lung tissue that protects against harmful inflammations.
Vesalius Biocapital and IFD launch life sciences fund
Healthcare investor Vesalius Biocapital has created a new investment vehicle in collaboration with the Portuguese National Promotional bank (IFD) aimed at investing in Portuguese life science companies.
Immunocore nabs US$40m from Gates Foundation
British T cell receptor specialist Immunocore Ltd will receive a US$40m investment from the the Bill & Melinda Gates Foundation to develop immunotherapies that fight tuberculosis and HIV.
.
CHMP candidate check
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) published the results of its September meeting.
EMA rejects Santhera’s DMD drug
The European Medicine Agency’s CHMP has rejected a type II extension application to Santhera Pharmaceutical’s coenzyme Q10 analogon idebenone (Raxone) as treatment for patients with Duchenne muscular dystrophy (DMD). Raxone was approved under exceptional circucumstances in September 2015 to treat visual impairment in patients with the rare eye disease LHON.